Functions PTEN, -tumor suppressor gene that is mutated in approximately 20% of cases of primary prostate cancer and in 50% of prostate cancer resistant to androgen deprivation therapy depend on other gene, ARID4B. This was reported by scientists at the Cancer Center. George Washington in «Nature Communications» magazine. Their new study provides a potential therapeutic target for the treatment of prostate cancer, supporting common mutation of PTEN.

For information on how to carry out the treatment of prostate cancer in Israel, the best specialists of the country, leave a request and we will contact you shortly.

"The loss of the tumor suppressor TEN due to a mutation or deletion is found not only in the case of prostate cancer, it plays an important role in the development of other cancer diseases. We wanted to learn more about, and PTEN genes from which the PTEN may depend, to identify new ways of treating cancer with this gene mutation We found that the PTEN gene is associated with ARID4B and ARID4B may be a new therapeutic target in prostate cancer "-. the researchers reported.

In a study of data from multiple cohorts of prostate cancer were studied. The researchers found that the cancer containing PTEN mutations are almost always retain ARID4B. One ARID4B gene function includes chromatin remodeling, which forms the basis of chromosomes. This "mutually exclusive" pattern between PTEN and ARID4B gave the team a first glimpse of its potential importance in prostate cancer.

In addition, studies have shown that inhibition of the expression of ARID4B in cancer cells with mutant PTEN significantly inhibits the growth of cancer cells and increases cell death. For comparison, using cancer cells containing a functional of PTEN, observed less pronounced effects, indicating that, depending on the ARID4B with PTEN-deficient prostate cancer.

The researchers were able to replicate these results using a mouse model of cancer of the prostate and remote PTEN. As expected, deletion of PTEN in mice leads to the development of prostate cancer, while in mice with a deletion of PTEN and ARID4B tumors do not develop. This suggests that PTEN function is dependent on the availability ARID4B.

Thus, scientists have identified ARID4B as a potential therapeutic target for prostate cancer. More research is needed to develop ARID4B targeting methods.


Date of publication: 
Wednesday, September 25, 2019